Dataset Information

Wearable Patch-Based Estimation of Oxygen Uptake and Assessment of Clinical Status during Cardiopulmonary Exercise Testing in Patients With Heart Failure.

ABSTRACT:

Background

To estimate oxygen uptake (VO₂) from cardiopulmonary exercise testing (CPX) using simultaneously recorded seismocardiogram (SCG) and electrocardiogram (ECG) signals captured with a small wearable patch. CPX is an important risk stratification tool for patients with heart failure (HF) owing to the prognostic value of the features derived from the gas exchange variables such as VO₂. However, CPX requires specialized equipment, as well as trained professionals to conduct the study.

Methods and results

We have conducted a total of 68 CPX tests on 59 patients with HF with reduced ejection fraction (31% women, mean age 55 ± 13 years, ejection fraction 0.27 ± 0.11, 79% stage C). The patients were fitted with a wearable sensing patch and underwent treadmill CPX. We divided the dataset into a training-testing set (n = 44) and a separate validation set (n = 24). We developed globalized (population) regression models to estimate VO₂ from the SCG and ECG signals measured continuously with the patch. We further classified the patients as stage D or C using the SCG and ECG features to assess the ability to detect clinical state from the wearable patch measurements alone. We developed the regression and classification model with cross-validation on the training-testing set and validated the models on the validation set. The regression model to estimate VO₂ from the wearable features yielded a moderate correlation (R² of 0.64) with a root mean square error of 2.51 ± 1.12 mL · kg^-1 · min^-1 on the training-testing set, whereas R² and root mean square error on the validation set were 0.76 and 2.28 ± 0.93 mL · kg^-1 · min^-1, respectively. Furthermore, the classification of clinical state yielded accuracy, sensitivity, specificity, and an area under the receiver operating characteristic curve values of 0.84, 0.91, 0.64, and 0.74, respectively, for the training-testing set, and 0.83, 0.86, 0.67, and 0.92, respectively, for the validation set.

Conclusions

Wearable SCG and ECG can assess CPX VO₂ and thereby classify clinical status for patients with HF. These methods may provide value in the risk stratification of patients with HF by tracking cardiopulmonary parameters and clinical status outside of specialized settings, potentially allowing for more frequent assessments to be performed during longitudinal monitoring and treatment.

SUBMITTER: Shandhi MMH

PROVIDER: S-EPMC7704799 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:Oxygen consumption ([Formula: see text]) provides established clinical and physiological indicators of cardiorespiratory function and exercise capacity. However, [Formula: see text] monitoring is largely limited to specialized laboratory settings, making its widespread monitoring elusive. Here we investigate temporal prediction of [Formula: see text] from wearable sensors during cycle ergometer exercise using a temporal convolutional network (TCN). Cardiorespiratory signals were acquired from a smart shirt with integrated textile sensors alongside ground-truth [Formula: see text] from a metabolic system on 22 young healthy adults. Participants performed one ramp-incremental and three pseudorandom binary sequence exercise protocols to assess a range of [Formula: see text] dynamics. A TCN model was developed using causal convolutions across an effective history length to model the time-dependent nature of [Formula: see text]. Optimal history length was determined through minimum validation loss across hyperparameter values. The best performing model encoded 218 s history length (TCN-VO2 A), with 187, 97, and 76 s yielding <3% deviation from the optimal validation loss. TCN-VO2 A showed strong prediction accuracy (mean, 95% CI) across all exercise intensities (-22 ml min-1, [-262, 218]), spanning transitions from low-moderate (-23 ml min-1, [-250, 204]), low-high (14 ml min-1, [-252, 280]), ventilatory threshold-high (-49 ml min-1, [-274, 176]), and maximal (-32 ml min-1, [-261, 197]) exercise. Second-by-second classification of physical activity across 16,090 s of predicted [Formula: see text] was able to discern between vigorous, moderate, and light activity with high accuracy (94.1%). This system enables quantitative aerobic activity monitoring in non-laboratory settings, when combined with tidal volume and heart rate reserve calibration, across a range of exercise intensities using wearable sensors for monitoring exercise prescription adherence and personal fitness.

Project description:BACKGROUND:This study aimed to compare the independent and incremental prognostic value of peak oxygen consumption (VO2) and minute ventilation/carbon dioxide production (VE/VCO2) in heart failure (HF) with preserved (HFpEF), midrange (HFmEF), and reduced (HFrEF) ejection fraction (LVEF). METHODS AND RESULTS:In 195 HFpEF (LVEF ?50%), 144 HFmEF (LVEF 40-49%), and 630 HFrEF (LVEF <40%) patients, we assessed the association of cardiopulmonary exercise testing variables with the composite outcome of death, left ventricular assist device implantation, or heart transplantation (256 events; median follow-up of 4.2 years), and 2-year incident HF hospitalization (244 events). In multivariable Cox regression analysis, greater association with outcomes in HFpEF than HFrEF were noted with peak VO2 (HR [95% confidence interval]: 0.76 [0.67-0.87] versus 0.87 [0.83-0.90] for the composite outcome, Pinteraction=0.052; 0.77 [0.69-0.86] versus 0.92 [0.88-0.95], respectively for HF hospitalization, Pinteraction=0.003) and VE/VCO2 slope (1.11 [1.06-1.17] versus 1.04 [1.03-1.06], respectively for the composite outcome, Pinteraction=0.012; 1.10 [1.05-1.15] versus 1.04 [1.03-1.06], respectively for HF hospitalization, Pinteraction=0.019). In HFmEF, peak VO2 and VE/VCO2 slope were associated with the composite outcome (0.79 [0.70-0.90] and 1.12 [1.05-1.19], respectively), while only peak VO2 was related to HF hospitalization (0.81 [0.72-0.92]). In HFpEF and HFrEF, peak VO2 and VE/VCO2 slope provided incremental prognostic value beyond clinical variables based on the C-statistic, net reclassification improvement, and integrated diagnostic improvement, with models containing both measures demonstrating the greatest incremental value. CONCLUSIONS:Both peak VO2 and VE/VCO2 slope provided incremental value beyond clinical characteristics and LVEF for predicting outcomes in HFpEF. Cardiopulmonary exercise testing variables provided greater risk discrimination in HFpEF than HFrEF.